An Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study
evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in
patients with advanced solid tumors.